Presentation Information
[Pj-038-2]Screening and baseline results from the donanemab phase 3 study in preclinical Alzheimer's disease [Encore Presentation]
Karen C. Holdridge1, Roy Yaari1, Melissa Williamson1, Alette M. Wessels1, Sergey Shcherbinin1, Vikas Kotari1, Naohisa Hatakeyama1, Pierre N. Tariot2, Robert Alexander2, Eric M. Reiman2, Jessica B. Langbaum2, John Sims1 (1.Eli Lilly and Company, USA, 2.Banner Alzheimer's Institute, USA)